---
title: 'FDA, Antares + Halozyme, GSK + Sierra, Ansa'
type: 'episode'
url: 'https://doc.social/episodes/fda-antares-halozyme-gsk-sierra-ansa'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-04-19'
audio: 'unavailable — the host retired the file'
---

# FDA, Antares + Halozyme, GSK + Sierra, Ansa

The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesFDAAntares + HalozymeGSK + SierraAnsa BiotechnologiesAbout the ShowLife S…

## Summary

The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA.

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[FDA](https://www.fda.gov/news-events/press-announcements/fda-takes-important-steps-increase-racial-and-ethnic-diversity-clinical-trials)
[Antares + Halozyme
](https://ir.halozyme.com/news/news-details/2022/Halozyme-to-Acquire-Antares-Pharma-to-Create-a-Specialty-Product-and-Drug-Delivery-Leader/default.aspx)[GSK + Sierra
](https://www.biospace.com/article/gsk-sierra-oncology-merger-to-enhance-momelotinib-for-rare-cancers/?s=79)[Ansa Biotechnologies**
**](https://www.biospace.com/article/releases/ansa-biotechnologies-closes-oversubscribed-68-million-series-a-financing-to-power-the-next-era-of-dna-enabled-industries/#:~:text=%2D%2D(BUSINESS%20WIRE)%2D%2D%20Ansa,Ventures%2C%20PEAK6%20Strategic%20Capital%2C%20Carbon)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.